Seres Therapeutics

Principal Investigator: Caterina Oneto MD

This phase 1 trial features an innovative approach to the treatment of Ulcerative Colitis – modification of the microbiome in order to induce colitis remission. Patients with mild to moderate ulcerative colitis are eligible. Patients on biologic therapies within 3 months of screening will be excluded. Patients who meet inclusion criteria and have no exclusion criteria will undergo a colonoscopy. If there is mild to moderate colitis of sufficient extent (at least 15 cm. of disease from the anal verge), the patient will be randomized to pretreatment with vancomycin or placebo followed by daily or weekly dosing of study drug (SER-287, a preparation of purified Eubacterial spores) for 8 weeks. There is a placebo arm (10/55 patients). Patients are followed clinically and by laboratory assessments, including stool microbiome assays. Follow-up colonoscopy to assess colitis response will be performed at 8 weeks. Safety assessments including telephone calls and office visits will be carried out for 38 weeks in total.

Please contact our Clinical Trial team if you have a patient who may be eligible.

Contact No: (212) 889-5544 x 152

Communication

Contact Us

Quick Contact

  • This field is for validation purposes and should be left unchanged.


Convenience

Our NYC Locations

232 East 30 Street
New York, NY 10016

233 Broadway
Suite 840
New York, NY 10279

100 Crosby Street
Suite 406
New York, NY 10012